NCT05817058View on ClinicalTrials.gov

First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

November 28, 2024

Study Completion Date

June 13, 2025

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

AFM28

AFM28 dose escalation

Trial Locations (5)

28041

Hospital Universitario 12 de Octubre, Madrid

31059

Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse

94805

Gustave Roussy, Villejuif

08907

Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona

CP 46026

Hospital Universitari i Politècnic La Fe, Valencia

Sponsors

Lead Sponsor

Affimed GmbH
All Listed Sponsors
lead

Affimed GmbH

INDUSTRY

NCT05817058 - First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter